Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy

Oncology Reports

Volumn 16, Issue 3, 2006, Pages 533-541

  Endo, Katsuhiko ^a   Sasaki, Hidefumi ^a   Yano, Motoki ^a   Kobayashi, Yoshihiro ^a   Yukiue, Haruhiro ^a   Haneda, Hiroshi ^a   Suzuki, Eriko ^a   Kawano, Osamu ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Epidermal growth factor receptor copy number; Epidermal growth factor receptor mutation; Gefitinib; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ARTICLE; CELL DIFFERENTIATION; FEMALE; GENE DOSAGE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 33749160146     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.3.533     Document Type: Article

References (30)

1. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302, 2002. (Pubitemid 35266289)
2. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003. (Pubitemid 46621858)
3. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22: 777-784, 2004. (Pubitemid 41103588)
4. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003. (Pubitemid 37432975)
5. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385, 1993. (Pubitemid 23156828)
6. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
7. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
8. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutation are common in lung cancer from 'never smokers' and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004. (Pubitemid 39209661)
9. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305: 1163-1167, 2004. (Pubitemid 39100331)
10. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE and Jänne PA: Gefitinib induces apoptosis in the EGFR L858R non-small cell lung cancer cell line H3255. Cancer Res 64: 7241-7244, 2004. (Pubitemid 39372059)
11. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807, 2003. (Pubitemid 46606235)
12. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655, 2005. (Pubitemid 40812628)
13. Sasaki H, Shimizu S, Endo K, et al: EGFR and ErbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006. (Pubitemid 41681596)
14. Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384, 2005.
15. Kawahara M, Furuse K, Segawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85: 939-943, 2001. (Pubitemid 33015993)
16. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520, 2005. (Pubitemid 47050841)
17. Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837, 2005.
18. Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501, 2005.
19. Kim KS, Jeong JY, Kim YC, et al: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11: 2244-2251, 2005.
20. Taron M, Ichinose Y, Rosell R, et al: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11: 5878-5885, 2005. (Pubitemid 41170316)
21. Greulich H, Chen TH, Freg W, et al: Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2: e313 (Epub ahead of print), 2005.
22. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
23. Jänne PA, Gurubhagavatula S, Yeap BY, et al: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa' on an expanded access study. Lung Cancer 44: 221-230, 2004. (Pubitemid 38482055)
24. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004. (Pubitemid 39665498)
25. Pegram M and Slamon D: Biological rationale for HER2/neu (c-erB2) as a target for monoclonal antibody therapy. Semin Oncol 5 (suppl 9): 13-19, 2000.
26. Brabender J, Danenber KD, Metzger R, et al: Epidermal growth factor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850-1855, 2001. (Pubitemid 32994816)
27. Yarden Y and Sliwkowski MX: Untangling the erbB2 signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
28. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of HER2 kinase domain in lung adenocarciomas. Cancer Res 65: 1642-1646, 2005. (Pubitemid 40478587)
29. Cappuzzo F, Garcia MV, Shigematsu H, et al: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor-positive non-small-cell lung cancer patients. J Clin Oncol 23: 5007-5018, 2005. (Pubitemid 46224007)
30. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005. (Pubitemid 41058345)